Alzheimer Disease
Reminyl XL now available in U.K. and Ireland
Published in Pain and Central Nervous System Week, July 11th, 2005
Reminyl XL is a new once-daily treatment for the symptoms of mild to moderately severe Alzheimer disease.
In clinical trials, Reminyl XL demonstrated comparable efficacy, safety and tolerability to twice-daily Reminyl tablets with the added convenience of once-daily dosing. In particular, a clinical study of 965 patients showed there was no significant difference in cognitive benefits between patients treated with Reminyl XL and Reminyl according to the Alzheimer Disease...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
More Articles from Pain and Central Nervous System Week
- Drug Abuse
Young drug abusers suffer brain damage similar to early Alzheimer Disease - Neural Reconstruction
Biodegradable elastomer developed for neural reconstruction applications - Neuroscience
Leech biology establishes a platform for investigating human nerve repair - Parkinson Disease
"Vicious cycle" of protein formation involved in Parkinson's disease - Spinal Cord Damage
Purdue scientists may have found key to halting spinal cord damage - Acetylcholine Receptors
Thalamocortical synapses studied, hypocretin and nicotine responses defined - More from this issue of Pain and Central Nervous System Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
